Skin
Delgocitinib (topical)
Tyrosine Kinase Inhibitor; Janus Associated Kinase (JAK) Inhibitor; Topical Skin Product
Other names: Anzupgo
FAA guidance
Acceptable in the FAA document cited.
The FAA's MedGuide lists delgocitinib (topical) (Anzupgo) as allowed, for dermatitis (Allergic/Atopic), with no wait after the first dose, after later doses or after the final dose, used as prescribed.
Track your medicationsMore detail: delgocitinib (topical)The rest of Crosscheck's reading, in plain wordsOpen
The MedGuide defines allowed as acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present, and says wait times are not determined solely by the medication: an extended observation period may be required to verify clinical stability of the condition.
Show the FAA's words: delgocitinib (topical)The official FAA wording: three passages, each with its document and dateOpen
Generic: delgocitinib (topical)
Brand Name: Anzupgo
Drug Class: Tyrosine Kinase Inhibitor; Janus Associated Kinase (JAK) Inhibitor; Topical Skin Product
Underlying Condition: Dermatitis (Allergic/Atopic)
Use: ALLOW
INITIAL Wait Time (after first dose): None
SUBSEQUENT Dose Wait Time (after each dose): None
DISCONTINUATION Wait Time (after final dose): None
Frequency Use Limit: As prescribed
ALLOWED: The medication is acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present.
Underlying Condition: Evaluating medication use requires considering the impact of safety of flight from both the medication and underlying condition. Wait times are not determined solely by the medication; an extended observation period may be required to verify clinical stability of the condition.